TY - JOUR
T1 - From Companion Diagnostics to Theranostics
T2 - A New Avenue for Alzheimer's Disease?
AU - Bolognesi, Maria Laura
AU - Gandini, Annachiara
AU - Prati, Federica
AU - Uliassi, Elisa
N1 - This work was supported by the University of Bologna (Grant RFO 2014). E.U. acknowledges the University of Bologna for a postdoctoral grant (assegno di ricerca).
PY - 2016/9/8
Y1 - 2016/9/8
N2 - The recent literature signals a growing paradigm shift toward integrating therapeutics and diagnostics rather than developing and deploying them separately. In this gradual move toward more effective and personalized medications, companion diagnostics are an intermediate stage. The next step may be "theranostics", in which single chemical entities are developed to deliver therapy and diagnosis simultaneously. This strategy has been successfully exploited in oncology and is now emerging as a possibility for Alzheimer's disease, where its feasibility has caught the attention of researchers from industry and academia. Medicinal chemists do not yet completely understand the nuances of theranostic action and consequently have not yet developed universally validated strategies for developing theranostic clinical applications against Alzheimer's disease. However, given the emerging indications of the potentially enormous benefits that theranostics may bring to the fight against this devastating disease, further rigorous research is warranted.
AB - The recent literature signals a growing paradigm shift toward integrating therapeutics and diagnostics rather than developing and deploying them separately. In this gradual move toward more effective and personalized medications, companion diagnostics are an intermediate stage. The next step may be "theranostics", in which single chemical entities are developed to deliver therapy and diagnosis simultaneously. This strategy has been successfully exploited in oncology and is now emerging as a possibility for Alzheimer's disease, where its feasibility has caught the attention of researchers from industry and academia. Medicinal chemists do not yet completely understand the nuances of theranostic action and consequently have not yet developed universally validated strategies for developing theranostic clinical applications against Alzheimer's disease. However, given the emerging indications of the potentially enormous benefits that theranostics may bring to the fight against this devastating disease, further rigorous research is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84986328567&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.6b00151
DO - 10.1021/acs.jmedchem.6b00151
M3 - Review article
C2 - 27124551
AN - SCOPUS:84986328567
SN - 0022-2623
VL - 59
SP - 7759
EP - 7770
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 17
ER -